PLSE vs. IRMD, SPNE, UTMD, ARAY, CTSO, NARI, IRTC, ICUI, NVCR, and IART
Should you be buying Pulse Biosciences stock or one of its competitors? The main competitors of Pulse Biosciences include Iradimed (IRMD), SeaSpine (SPNE), Utah Medical Products (UTMD), Accuray (ARAY), Cytosorbents (CTSO), Inari Medical (NARI), iRhythm Technologies (IRTC), ICU Medical (ICUI), NovoCure (NVCR), and Integra LifeSciences (IART). These companies are all part of the "surgical & medical instruments" industry.
Iradimed (NASDAQ:IRMD) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings, profitability and community ranking.
Iradimed has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.
Iradimed has a net margin of 26.48% compared to Iradimed's net margin of 0.00%. Pulse Biosciences' return on equity of 24.63% beat Iradimed's return on equity.
In the previous week, Pulse Biosciences had 3 more articles in the media than Iradimed. MarketBeat recorded 5 mentions for Pulse Biosciences and 2 mentions for Iradimed. Pulse Biosciences' average media sentiment score of 1.43 beat Iradimed's score of 0.58 indicating that Iradimed is being referred to more favorably in the media.
Iradimed has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500.
Iradimed received 4 more outperform votes than Pulse Biosciences when rated by MarketBeat users. However, 65.17% of users gave Pulse Biosciences an outperform vote while only 64.69% of users gave Iradimed an outperform vote.
Iradimed presently has a consensus price target of $62.50, suggesting a potential upside of 47.16%. Given Pulse Biosciences' higher possible upside, research analysts plainly believe Iradimed is more favorable than Pulse Biosciences.
92.3% of Iradimed shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 42.6% of Iradimed shares are held by company insiders. Comparatively, 71.5% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Iradimed beats Pulse Biosciences on 12 of the 17 factors compared between the two stocks.
Get Pulse Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pulse Biosciences Competitors List
Related Companies and Tools
